Ibutamoren (MK-677) Side Effects: Why It Is Not FDA Approved
Ibutamoren (MK-677) is an orally active growth hormone secretagogue that stimulates the ghrelin receptor. It is investigational and not approved by the FDA or TGA for any therapeutic use. Published clinical trials have identified specific safety signals that prevented further development, including an increased heart-failure signal in an elderly population. WADA includes it on the prohibited list.
Ibutamoren (MK-677) is not FDA-approved and lacks controlled human safety data. Not FDA-approved. Not TGA-approved. Investigational. Development for elderly fall prevention was discontinued after a heart failure signal. WADA prohibits its use in competitive sport. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- Ibutamoren (MK-677) is investigational. Not FDA-approved. Not TGA-approved.
- Published Merck-sponsored trials in elderly patients reported an increased heart-failure signal, after which the development programme for fall prevention was discontinued.
- Other trial-reported effects include increased appetite, glucose intolerance, oedema, joint and muscle aches, and modest elevations in cortisol and prolactin.
- WADA prohibits ibutamoren use in competitive sport (S2 anabolic agents).
- Compounded or gray-market MK-677 is not regulated for purity or potency.
What is Ibutamoren (MK-677), and what is it marketed for?
Ibutamoren mesylate (MK-677). Ibutamoren is a non-peptide ghrelin receptor agonist that stimulates growth hormone release from the pituitary, raising IGF-1 levels. Studies reviewed in the peer-reviewed literature describe pharmacokinetic and pharmacodynamic effects consistent with sustained GH and IGF-1 elevation following oral dosing.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| Heart failure signal | Elderly hip-fracture trial reported a higher rate of heart failure with ibutamoren vs placebo, leading to discontinuation of the development programme | Published Merck trial data |
| Glucose intolerance and insulin resistance | Raised blood glucose, reduced insulin sensitivity in trials | Common to GH-axis stimulation |
| Fluid retention / oedema | Swelling, joint pain, muscle aches | Reported across MK-677 trials |
| Increased appetite | Ghrelin receptor agonism raises appetite | Consistent with mechanism |
| Elevated cortisol and prolactin | Modest increases reported in trials | Common to GH-secretagogues |
| WADA prohibited | Use in competitive sport is prohibited under WADA Code | S2 anabolic agents |
| Long-term safety | Not characterised beyond limited trial durations | Heart failure signal halted long-term development |
Taking Ibutamoren (MK-677) alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About Ibutamoren (MK-677)
No. MK-677 is investigational. It is not approved by the FDA or TGA for any therapeutic use. Its development for fall prevention in elderly hip-fracture patients was halted by Merck after a heart-failure signal in a clinical trial.
Published clinical trials have reported increased appetite, glucose intolerance, fluid retention and oedema, joint and muscle pain, and modest elevations in cortisol and prolactin, all consistent with sustained activation of the growth-hormone axis. An elderly hip-fracture trial reported a higher rate of heart failure with MK-677 than with placebo.
Yes. WADA prohibits MK-677 under section S2 of the prohibited list (anabolic agents). Athletes subject to anti-doping testing should not use it.
Compounded or gray-market MK-677 is not FDA-regulated for purity or potency. The published safety signals plus the absence of pharmaceutical-grade controls are why most pharmacy reviewers advise against unsupervised use.
References
- Adunsky A et al. MK-677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture. Arch Gerontol Geriatr. 2011;53(2):183-189. Source.
- Nass R et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. Source.
- World Anti-Doping Agency. WADA Prohibited List. Source.
- U.S. Food & Drug Administration. FDA position on bulk drug substances for compounding. Source.